COPD

Questions discussed in this category

Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?

Do the findings of a recent large cohort study (Beasly et al., PMID 38029294) in which bronchodilator response did not distinguish between asthma and ...

1 Answer available

Will you incorporate ensifentrine in the treatment regimen of patients with COPD on baseline dual or triple inhaler therapy?

1 Answer available

What is your threshold to start triple therapy in mild to moderate asthma/COPD overlap with minimal functional limitation?

1 Answer available

What patient factors prompt you to consider starting dupilumab in patients with COPD?

Does active smoking status influence this decision?

2 Answers available

Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?

2 Answers available

Are the results of the BOREAS trial generalizable to non-white populations?

The cohort in the study was predominantly white. Do these results highlight significant disparities in COPD care?

2 Answers available

Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?

If so, would this be a consideration in all patients regardless of active smoking status? FeNO in active smokers has been questioned, could this have ...

2 Answers available

How do you choose between azithromycin and roflumilast in the management of a patient with severe COPD who remains symptomatic with frequent exacerbations despite maximal dose LABA/LAMA/ICS with demonstrated compliance and proper inhaler technique?

1 Answer available

Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?

1 Answer available

Is there a role for biologic therapies in asthma-COPD overlap syndrome with evidence of type 2 inflammation?

2 Answers available

Papers discussed in this category

American journal of respiratory and critical care medicine, 2023 Aug 15

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).

COPD

Questions discussed in this category

Papers discussed in this category

Related Topics